Stifel Nicolaus Issues Positive Forecast for Insmed (NASDAQ:INSM) Stock Price

Insmed (NASDAQ:INSM) had its target price increased by equities researchers at Stifel Nicolaus from $205.00 to $208.00 in a research report issued to clients and investors on Tuesday,Benzinga reports. The firm currently has a “buy” rating on the biopharmaceutical company’s stock. Stifel Nicolaus’ price target points to a potential upside of 49.53% from the stock’s previous close.

Several other analysts have also recently weighed in on INSM. The Goldman Sachs Group lifted their price objective on Insmed from $225.00 to $258.00 and gave the company a “buy” rating in a research report on Monday, December 15th. Morgan Stanley set a $166.00 target price on Insmed in a research report on Friday, February 20th. Barclays initiated coverage on Insmed in a research report on Tuesday, January 27th. They set an “overweight” rating and a $231.00 price target on the stock. Citigroup reaffirmed an “outperform” rating on shares of Insmed in a research note on Thursday, December 18th. Finally, Wells Fargo & Company decreased their price objective on Insmed from $208.00 to $175.00 and set an “overweight” rating for the company in a report on Monday. Three investment analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Insmed has a consensus rating of “Buy” and a consensus price target of $204.62.

Insmed Trading Down 3.4%

Shares of Insmed stock traded down $4.88 during midday trading on Tuesday, reaching $139.11. 285,640 shares of the company’s stock traded hands, compared to its average volume of 2,444,458. The stock has a 50 day moving average of $151.48 and a 200-day moving average of $166.27. Insmed has a 12 month low of $60.40 and a 12 month high of $212.75. The company has a market cap of $29.98 billion, a PE ratio of -21.70 and a beta of 1.13. The company has a debt-to-equity ratio of 0.76, a quick ratio of 3.54 and a current ratio of 3.83.

Insmed (NASDAQ:INSM) last issued its quarterly earnings data on Thursday, February 19th. The biopharmaceutical company reported ($1.54) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.07) by ($0.47). The company had revenue of $263.84 million for the quarter, compared to analysts’ expectations of $263.97 million. Insmed had a negative net margin of 210.54% and a negative return on equity of 168.36%. The firm’s revenue for the quarter was up 152.6% compared to the same quarter last year. During the same period in the previous year, the firm posted ($1.32) earnings per share. As a group, equities analysts expect that Insmed will post -4.56 EPS for the current fiscal year.

Insider Activity at Insmed

In other news, insider Michael Alexander Smith sold 640 shares of the stock in a transaction on Tuesday, February 3rd. The stock was sold at an average price of $156.27, for a total transaction of $100,012.80. Following the transaction, the insider directly owned 56,397 shares of the company’s stock, valued at $8,813,159.19. This represents a 1.12% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, COO Roger Adsett sold 791 shares of the firm’s stock in a transaction on Tuesday, February 3rd. The stock was sold at an average price of $156.17, for a total value of $123,530.47. Following the completion of the transaction, the chief operating officer owned 106,810 shares in the company, valued at approximately $16,680,517.70. This trade represents a 0.74% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 189,651 shares of company stock worth $31,533,654. Company insiders own 3.00% of the company’s stock.

Institutional Investors Weigh In On Insmed

A number of large investors have recently made changes to their positions in INSM. CIBC Private Wealth Group LLC boosted its holdings in shares of Insmed by 42.1% in the third quarter. CIBC Private Wealth Group LLC now owns 179 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 53 shares during the last quarter. Kingsview Wealth Management LLC increased its holdings in Insmed by 2.7% during the third quarter. Kingsview Wealth Management LLC now owns 2,321 shares of the biopharmaceutical company’s stock valued at $334,000 after buying an additional 60 shares during the last quarter. Choreo LLC raised its position in Insmed by 2.9% in the third quarter. Choreo LLC now owns 2,319 shares of the biopharmaceutical company’s stock worth $334,000 after acquiring an additional 65 shares during the period. EverSource Wealth Advisors LLC boosted its stake in shares of Insmed by 10.2% during the 4th quarter. EverSource Wealth Advisors LLC now owns 747 shares of the biopharmaceutical company’s stock worth $130,000 after acquiring an additional 69 shares during the last quarter. Finally, ORG Partners LLC boosted its stake in shares of Insmed by 12.7% during the 4th quarter. ORG Partners LLC now owns 657 shares of the biopharmaceutical company’s stock worth $114,000 after acquiring an additional 74 shares during the last quarter.

Key Stories Impacting Insmed

Here are the key news stories impacting Insmed this week:

• Positive Sentiment: Company announces positive topline Phase 3b ENCORE results: the study met its primary and multiplicity‑controlled secondary endpoints, showed clinically meaningful respiratory symptom and culture conversion improvements, and Insmed plans to file a supplemental NDA in the second half of 2026 and submit data to Japan’s PMDA. PR Newswire: Insmed Announces Positive Topline Results
• Positive Sentiment: Market response and coverage show immediate investor enthusiasm: multiple outlets report a jump in shares after the trial data, highlighting a larger market opportunity for ARIKAYCE in MAC lung disease. Proactive: Insmed shares rise on positive late-stage trial results
• Positive Sentiment: Bank of America raised its price target to $213 and kept a Buy rating, signaling bullish analyst conviction and implying substantial upside from current levels. Benzinga: BofA raises price target
• Neutral Sentiment: Wells Fargo trimmed its price target from $208 to $175 but maintained an Overweight rating — a mixed read: analysts are still positive on the story but some see less near‑term upside. Benzinga: Wells Fargo lowers price target
• Neutral Sentiment: Insmed hosted an investor/shareholder call; the transcript provides additional detail and management color but did not introduce new clinical surprises beyond the topline release. Seeking Alpha: Shareholder/Analyst Call Transcript
• Negative Sentiment: Insider selling: CEO reported a sale of approximately $1.54M of INSM stock, which may raise governance or timing concerns for some investors despite the positive clinical news. American Banking News: Insider Selling

About Insmed

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.